Receiver-operating characteristic (ROC) curve analysis of cathepsin D and pS2 in breast disease; Results from a prospective study

Anticancer Research

Volumn 19, Issue 4 C, 1999, Pages 3463-3467

  Eskelinen, Matti ^a,b   Kataja, Vesa ^a   Hämäläinen, Esa ^a   Kosma, Veli Matti ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Breast cancer; Cathepsin D; pS2; ROC analysis

Indexed keywords

CATHEPSIN D; PROTEIN PS2;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOSOL; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST DISEASES; BREAST NEOPLASMS; CATHEPSIN D; CYTOSOL; FEMALE; GROWTH SUBSTANCES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROTEINS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEINS;

EID: 0033406243     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Spyralos F, Brouillet JP, Defrenne A, Hacene K, Rouess J, Maudelonde T, Brunet M, Andrieu C, Desplaces A and Rochefort H: Cathepsin D: An independent prognostic factor for metastasis of breast cancer, Lancet 2: 1115-1118, 1989.
2. Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, Paolucci F, Pau B, Rasmussen BB and Rose C: Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49: 6008-6014, 1989.
3. Tandon AK, Chamness GC, Chirgwin JM and McGuire WL: Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297-302, 1990.
4. Kute TE, Shao ZM, Sugg NK, Long RT, Russel GB and Case D: Cathepsin D as a prognostic indicator for node negative breast cancer patients using immunoassays and enzymatic assays. Cancer Res 52: 5198-5203, 1992.
5. Predine J, Spyratos F, Prud'homme JF, Andrieu C, Hacene K, Brunet M, Pallud C and Milgrom E: Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumours and normal breast tissues. Cancer 69: 2116-2123, 1992.
6. Foekens JA, Van Putten WLJ, Portengen H, de Koning HYWCM, Thirion B, Alexieva- Figusch J and Klijn JGM: Prognostic value of pS2 and Cathepsin D in 710 human primary breast tumors: Multivariate analysis. J Clin Oncol 11: 899-908, 1993.
7. Foekens JA, Rio MC, Seguin P, van Putten WLJ, Fauque J, Nap M, Klijn JGM and Chambon P: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50: 3832-3837, 1990.
8. Gion M, Mione R, Papagallo R, Gatti C, Nascimben O, Bari M, Leon AE, Vinante O, Bruscagnin G: PS2 in breast cancer-alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Br J Cancer 68: 374-379, 1993.
9. Hahnel E, Robbins P and Hahnel R: Expression of the pS2 gene in normal breast tissue. Breast Cancer Res Treat 28: 295-297, 1993.
10. Ardavanis A, Gerakini F, Amanatidou A, Scorilas A, Pateras C, Garoufali A, Pissakas G, Stravolemos K, Apostolikas N, Yiotis I: Relationships between Cathepsin D, pS2 protein and hormonal receptors in breast cancer cytosols: inconsistency with their established prognostic significance. Anticancer Res 17: 3665-3670, 1997.
11. Ferrandina G, Scambia G, Bardelli F, Benedetti Panici P, Mancuso S and Messori A: Relationship between cathepsin D content and disease-free survival in node-negative breast cancer patients.; a meta-analysis. Br J Cancer 76: 661-666, 1997.
12. Feinstein, A.R: Clinical epidemiology. The Achitecture of Clinical Research. W.B. Saunders. Philadelphia, 1985.
13. UICC International Union Against Cancer: TNM Classification of Malignant Tumours. Berlin, 1987
14. Forrest APM: Total mastectomy and axillary node sample. In: Atlas of General Surgery (Dudley H, Carter DC and Russell RCG, eds). London, Butterworths, pp 960-969, 1986.
15. Fisher B, Wolmark N, Fisher E, Deutsch M: Lumpectomy and axillary dissection for breast cancer. Surgical, pathological and radiation considerations. World J Surg 9: 692-698, 1985.
16. Galen RS, Gambino SR: Beyond Normality. The Predictive value and Efficiency of Medical Diagnosis. John Wiley & Sons, New York, 1975.
17. Beck JR: Likelihood ratios. Another enhancement of sensitivity and specificity. Arch Pathol Lab Med 110: 685-686, 1986.
18. Lavelle SM and Kanagaratnam B: The information value of clinical data. Int J Biomed Comput 26: 203-209, 1990.
19. Eskelinen M, Tikanoja S and Collan Y: Clinical evaluation of tumor marker CA 50 in breast cancer diagnostics. Surg Res Comm 6: 107-113, 1989.
20. Eskelinen M, Pasanen P, Janatuinen E, Pettersson K, Linnane A and Alhava E: Small Intestinal Mucin Antigen (SIMA): A novel tumour marker in colorectal cancer? Anticancer Res 15: 2351-2356, 1995.
21. Haglund C, Roberts P, Jalanko H and Kuusela P: Tumour markers CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol 27: 169-174, 1992.
22. Nilsson O, Johansson C, Glimelius B, Persson B, Norgaard-Pedersen B, Andren-Sandberg A and Lindholm L: Sensitivity and specificity of CA 242 in gastrointestinal cancer. A comparison with CEA. CA 50 and CA 19-9. Br J Cancer 65: 215-221, 1992.
23. Pasanen P, Eskelinen M, Partanen K, Pikkarainen P, Penttila I and Alhava E: Receiver operating characteristics curve (ROC) analysis of the serum tumour markers CEA, CA 50 and CA 242 in the diagnosis of pancreatic cancer; results from a prospective study. Br J Cancer 67: 852-855, 1993.